A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer
Status:
Terminated
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
When kidney cancer spreads beyond the kidney, it is known as metastatic kidney cancer. This
is very difficult to treat and almost all patients will die of their disease within 2 years
of the diagnosis.
Sunitinib and other related drugs (e.g. pazopanib) have become standard therapy for untreated
patients with metastatic kidney cancer. They target a growth factor known as VEGF which is
important in treating kidney cancer. Although the results with this drug are impressive,
patients develop resistance to the drug and stop therapy. It is currently standard practice
is to give everolimus when resistance to sunitinib occurs; this is associated with clear
clinical benefit.
However the average time to cancer regrowth with everolimus is only 5 months. It is thought
this might be because, everolimus only partially inhibits its target (TORC 1 and TORC 2).
Therefore further improvement in treating patients is required. AZD2014 is a promising new
drug which does inhibit both TORC 1 and TORC 2 and is therefore worthy of investigation in
renal cancer as it theoretically could may have advantages over everolimus. Therefore study
compares AZD2014 to everolimus in the setting where everolimus is used as standard of care.
(e.g. in patients who have failed drug like sunitinib). The study is a randomised trial
allowing us to quantify the benefit and potential for further development of AZD2014. Repeat
Xrays (CT scans) will be used to assess if the new drug delays tumour growth. Patients will
be closely followed up in clinic to ensure safety. A maximum of 122 patients will be
recruited into this multi centre national trial. The primary goal of the study is to
investigate if AZ2014 delays the time for cancer regrowth (time to progression) compared to
everolimus.